An interventional study of EMOCARE software in Major Depressive Disorder (MDD), sponsored by Emobot. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Emobot · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.
Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 73rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 10 that started in 2025, is one of 50 with no phase, reaches primary completion later than 13 of the 30 other live ones, and was the 109th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 232 across the 106 interventional studies, 128 across the 21 observational. Of the 84 that completed or were terminated, 31 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 127 have an industry lead sponsor. The 10 most frequent:
Emobot is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Emobot has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
8 of the studies in Depressive Disorder, Major with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT06234176Centre Hospitalier EsquirolImpact of Psychomotor Therapy on the Quality of Life in Depression | 2027-02 |
| NCT06601140EmobotEvaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode | 2027-02-04 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 127 studies in Depressive Disorder, Major with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from mild to moderately severe depressive episod. It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of patient). The main questions it aims to answer are as follows:
Does EMOCARE provide consistent results compared with tools already used in current practice? What are the medical problems encountered by participants when using EMOCARE?
The researchers will compare EMCOCARE to various questionnaires usually used in the management of patients suffering from depression (PHQ-9, MADRS, GAD-7, BDI-II, EQ-5D-5L).
Participants who agree to take part in the study, during a selection visit, will be able to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: EMOCARE software
Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
Change of scores EMOCARE
Absolute difference
Time frame: From baseline to 6 weeks
Change of scores PHQ-9 self-administrered
Absolute difference
Time frame: From baseline to 6 weeks
Score EMOCARE
Time frame: At baseline, at 2 weeks, at 4 weeks
Change of EMOCARE score
Time frame: From baseline to 2 weeks, from baseline to 4 weeks
Score PHQ-9 self administered
Time frame: At baseline, at 2 weeks, at 4 weeks, at 6 weeks
Change of score PHQ-9 self administered
Time frame: From baseline to 2 weeks, From baseline to 4 weeks
Score PHQ-9 administered by an investigator
Time frame: At baseline, at 6 weeks
Change of score PHQ-9 administered by an investigator
Time frame: From baseline to 6 weeks
Score MADRS administered by an investigator
Time frame: At baseline, at 6 weeks
Change of MADRS administered by an investigator
Time frame: From baseline to 6 weeks
Score BDI-II
Time frame: At baseline, at 6 weeks
Change of BDI-II
Time frame: From baseline to 6 weeks
Score BDI-II
Time frame: At baseline, at 2 weeks, at 4 weeks, at 6 weeks
Change of BDI-II
Time frame: From baseline to 2 weeks, from baseline to 4 weeks, from baseline to 6 weeks
EMOCARE operating time
Time frame: From baseline to 2 weeks, from baseline to 4 weeks, from baseline to 6 weeks
EQ-5D-5L
Time frame: At baseline, at 6 weeks
Number of patient with adverse event
Time frame: At baseline, at 2 weeks, at 3 weeks, at 4 weeks, at 6 weeks
Acceptability of medical device questionnaire
Time frame: At baseline, at 6 weeks
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.
Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 22 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emobot